10-Q: Inovio Q3 2025: Mounting Losses, Going Concern Warning

Inovio Pharmaceuticals reported significant net losses for Q3 2025, with cash reserves projected to last only into Q2 2026, raising substantial doubt about its ability to continue as a going concern.

Summary

• Incurred a net loss of $45.5 million for the three months ended September 30, 2025, and $88.7 million for the nine months ended September 30, 2025.
• Reported an accumulated deficit of $1.8 billion and a working capital deficit of $(14.6) million as of September 30, 2025.
• Cash, cash equivalents, and short-term investments totaled $50.8 million as of September 30, 2025, expected to fund planned operations into the second quarter of 2026.
• Management believes there is substantial doubt about the company's ability to continue as a going concern beyond the first quarter of 2026.
• Completed the rolling submission of its Biologic License Application (BLA) for INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP) to the U.S. FDA in November 2025, requesting priority review.
• Resolved a manufacturing issue with the single-use disposable administration component of the CELLECTRA 5PSP device in Q1 2025, which had previously delayed the BLA submission.
• Research and development expenses decreased by 29% to $13.3 million for Q3 2025 and by 30% to $43.9 million for the nine months ended September 30, 2025, primarily due to lower INO-3107 expenses, drug manufacturing, and expensed inventory.
• General and administrative expenses decreased by 8.6% to $7.9 million for Q3 2025 and by 13.3% to $25.5 million for the nine months ended September 30, 2025.
• Received net proceeds of $22.4 million from a July 2025 public offering and $1.1 million from At-the-Market sales during the nine months ended September 30, 2025.

Sentiment

Score: 3

Explanation: The company faces severe liquidity challenges, evidenced by a substantial accumulated deficit, negative working capital, and a going concern warning. While there is progress on INO-3107's BLA submission, the financial instability and significant accumulated deficit overshadow these developments, indicating high risk and a precarious financial position.

Positives

• Completed the rolling submission of its Biologic License Application (BLA) for INO-3107 for RRP to the U.S. FDA in November 2025, requesting priority review.
• Resolved a manufacturing issue with the CELLECTRA 5PSP device in Q1 2025, which had previously delayed the INO-3107 BLA submission.
• INO-3107 Phase 1/2 clinical trial data showed 81% of RRP patients experienced a reduction of one or more surgeries at Year 1 post-treatment, with 91% continuing this reduction by the end of Year 2.
• INO-3107 demonstrated a 78% reduction in mean annual surgeries at Year 2 compared to the year prior to treatment.
• Gained alignment with the FDA on the design of a planned Phase 3 trial for INO-3112 for oropharyngeal squamous cell carcinoma (OPSCC) and received initial feedback from European regulatory authorities.
• Research and development expenses decreased by 29% for the three months and 30% for the nine months ended September 30, 2025, compared to the prior year periods.
• General and administrative expenses decreased by 8.6% for the three months and 13.3% for the nine months ended September 30, 2025, compared to the prior year periods.

Negatives

• Reported a significant net loss of $45.5 million for the three months ended September 30, 2025, compared to $25.2 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, increased to $88.7 million from $87.9 million in the prior year period.
• Accumulated deficit reached $1.8 billion as of September 30, 2025.
• Working capital deteriorated to a deficit of $(14.6) million as of September 30, 2025, from a positive $62.5 million as of December 31, 2024.
• Cash, cash equivalents, and short-term investments decreased to $50.8 million as of September 30, 2025, from $94.1 million as of December 31, 2024.
• Management believes there is substantial doubt about the company's ability to continue as a going concern beyond the first quarter of 2026.
• Revenue from collaborative arrangements decreased to $65,343 for the nine months ended September 30, 2025, from $100,762 in the prior year period.
• A change in the fair value of common stock warrant liabilities resulted in a $(22.5) million expense for the three months and $(20.7) million for the nine months ended September 30, 2025.
• Interest income decreased due to a lower short-term investment balance.
• Ongoing litigation with VGXI, Inc. and GeneOne Life Science, Inc. continues without a set trial date.

Risks

• Incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable.
• Limited sources of revenue and success is dependent on ability to develop DNA medicines and proprietary device technology.
• Will need substantial additional capital to develop DNA medicines and proprietary device technology, which may prove difficult or costly to obtain.
• Do not currently have sufficient working capital to fund planned operations for the next twelve months and substantial doubt exists as to ability to continue as a going concern.
• If unable to obtain FDA approval of proprietary devices and DNA medicine candidates, will not be able to commercialize them in the United States, especially as drug-device combination products.
• DNA medicines and CELLECTRA delivery devices are novel approaches; negative perception of efficacy, safety, or tolerability could adversely affect business or regulatory approvals.
• If the company and contract manufacturers fail to produce proprietary devices and DNA medicine candidates in required volumes, on time, or in compliance with regulations, development and commercialization may be delayed.
• Loss or inability to secure collaborators or partners, or inadequate resource allocation by collaborators, will harm product development and potential for profitability.
• Agreements with government agencies are subject to termination and uncertain future funding, which could negatively impact development or require alternative funding.
• Currently subject to litigation and may become subject to additional litigation, which could harm business, financial condition, and reputation.
• Faces intense and increasing competition, and new, disruptive technologies from competitors may impede ability to develop and commercialize DNA medicines.
• Collaborations with Chinese companies and reliance on clinical materials manufactured in China expose the company to uncertainties regarding Chinese laws, trade wars, political unrest, or unstable economic conditions.
• It is difficult and costly to generate and protect intellectual property and proprietary technologies, and protection may not be ensured.
• Being sued for infringing intellectual property rights of third parties would be costly and time-consuming, with an unfavorable outcome having a material adverse effect.
• Subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies, and other obligations related to data privacy and security; failure to comply could lead to material adverse business consequences.
• Pursuing accelerated approval for INO-3107 or other product candidates may not lead to a faster development or regulatory review or approval process and does not increase the likelihood of marketing approval.
• Even if products receive regulatory approval, will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and penalties for non-compliance.
• Developing some investigational DNA medicines using new endpoints or methodologies for diseases with little clinical experience, which the FDA or other regulatory authorities may not consider clinically meaningful.
• May be unsuccessful in obtaining new Orphan Drug Designations or unable to obtain or maintain the benefits associated with Orphan Drug Designation, including potential for orphan drug exclusivity.
• A breakthrough therapy designation or fast track designation by the FDA may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the drug will receive marketing approval.
• Reliance on third parties to conduct clinical trials; if these third parties do not successfully carry out their contractual duties or meet expected deadlines, regulatory approval or commercialization may not be obtained.
• Dependent on single-source suppliers for some components and materials used in, and processes required to develop, proprietary device and DNA medicine candidates.
• Currently has only a small marketing organization and no sales organization; if unable to establish capabilities or enter into agreements with third parties, may not generate product revenues.
• If products for which regulatory approval is received do not achieve broad market acceptance, revenues from sales will be limited.
• Subject to uncertainty relating to coverage and reimbursement policies which, if not favorable, could hinder or prevent commercial success.
• Potential product liability exposure; if successful claims are brought, substantial liability may be incurred.
• Healthcare reform measures could hinder or prevent products' commercial success.
• Employees, principal investigators, and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and insider trading.
• Employee litigation and unfavorable publicity could negatively affect future business.
• An active trading market for common stock may not be sustained.
• The price of common stock has been and may continue to be volatile, and an investment could decline substantially in value.
• Broad discretion in the use of cash, cash equivalents, and investments, and may not use them effectively.
• Anti-takeover provisions under charter documents and Delaware law could delay or prevent a change of control.
• Ability to utilize net operating loss carryforwards and certain other tax attributes may be limited.
• Quarterly operating results may fluctuate significantly.
• Results of operations and liquidity needs could be materially affected by market fluctuations and general economic conditions.
• Adverse developments affecting the financial services industry could adversely impact business, financial condition, and results of operations.
• If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the company, its stock price and trading volume could decline.
• The issuance of additional stock in connection with financings, acquisitions, investments, stock incentive plans or otherwise will dilute all other stockholders.
• Incurs significant costs and demands upon management as a result of being a public company.
• Changes in tax laws could adversely affect business and financial condition.
• The increasing use of social media platforms presents new risks and challenges.
• Actual or perceived failure, or the failure of third parties, to comply with stringent and evolving data privacy and security obligations could lead to material adverse business consequences.

Future Outlook

The company expects to continue incurring significant net losses for the foreseeable future due to ongoing research and development. Current cash, cash equivalents, and short-term investments are projected to support planned operations only into the second quarter of 2026. Substantial additional capital will be required to fund future research, development, and potential commercialization efforts. The company aims to receive FDA file acceptance for its INO-3107 BLA by the end of 2025, with a potential priority review completion within six months following the 60-day filing period.

Management Comments

• Management believes that there is substantial doubt about the Company's ability to continue as a going concern beyond the first quarter of 2026.

Industry Context

Inovio operates in the highly competitive clinical-stage biotechnology sector, specializing in novel DNA medicines and proprietary CELLECTRA delivery devices for HPV-associated diseases, cancer, and infectious diseases. The field of DNA medicines is still emerging, with no FDA-approved DNA medicines to date, leading to increased regulatory scrutiny and potential public perception challenges. The RRP market, where INO-3107 is a lead candidate, recently saw the FDA approval of PAPZIMEOS (zopapogene imadenovec-drba), intensifying competition. The company faces competition from large pharmaceutical companies with extensive resources and numerous development-stage biotechnology firms, all vying for market share and regulatory approvals in gene-based therapies and immunotherapies. The regulatory environment for gene-based therapies is complex and evolving, with new legislation and judicial decisions potentially impacting development and commercialization pathways.

Comparison to Industry Standards

• INO-3107 for RRP will compete with PAPZIMEOS (zopapogene imadenovec-drba), which has already received FDA approval for the treatment of RRP in adults.
• In the broader HPV vaccine market, established players like Merck and GlaxoSmithKline have commercialized preventive vaccines against HPV.
• For high-grade cervical dysplasia, the current standard of care in high-income countries is the Loop Electrosurgical Excision Procedure (LEEP), while Advaxis, Genexine, and Gilead Sciences have therapeutic cervical cancer product candidates under development.
• The company faces competition from large pharmaceutical companies such as Janssen Pharmaceuticals, Sanofi-Aventis, GlaxoSmithKline, Merck, Pfizer, Roche, AbbVie, Novartis, Bristol-Myers Squibb, and AstraZeneca, which possess significantly greater financial, scientific, marketing, and human resources.
• Competition also comes from development-stage biotechnology companies involved in various vaccine and immunotherapy technologies, including CureVac, Dynavax, Genexine, Imunon, Iovance, Nektar, Nykode, Precigen, Zydus, and Vir Biotechnology.

Corporate Governance

Legal Proceedings

• Ongoing litigation initiated in June 2020 against VGXI, Inc. and GeneOne Life Science, Inc. (collectively VGXI) in the Court of Common Pleas of Montgomery County, Pennsylvania, alleging material breach of a supply agreement.
• VGXI filed counterclaims in July 2020, alleging breach of the supply agreement, misappropriation of trade secrets, and unjust enrichment.
• A trial date for the litigation has not been set, and the company intends to aggressively prosecute its claims and vigorously defend against VGXI's counterclaims.

Related Party Transactions

• Investment in Plumbline Life Sciences, Inc. (PLS): The company owned 597,808 shares (15.7% ownership) valued at $2.5 million as of September 30, 2025. Dr. David B. Weiner, a company director, acts as a consultant to PLS.
• Collaborative research agreements with The Wistar Institute: Dr. David B. Weiner is a director and Executive Vice President of Wistar. The company reimburses Wistar for research costs and receives sub-grants, recording $220,000 and $821,000 as contra-research and development expense for the three and nine months ended September 30, 2025, respectively.
• Geneos Therapeutics, Inc.: The company held 23% of outstanding equity as of September 30, 2025. Chief Scientific Officer Dr. Laurent Humeau is on Geneos' Board, and Dr. David B. Weiner is Chairman of its Scientific Advisory Board. The company exclusively licenses its immunotherapy platform and CELLECTRA technology to Geneos for personalized cancer therapies.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future capital raises, potential loss of investment due to the substantial doubt about the company's ability to continue as a going concern, and continued stock price volatility.
• Employees may experience uncertainty regarding job security and the long-term viability of the company due to the going concern warning, potentially impacting morale and retention.
• Future customers could face delays in accessing potential products if regulatory approvals are not secured in a timely manner or if manufacturing issues persist.
• Suppliers and creditors may face increased risk of delayed or non-payment if the company's liquidity challenges worsen.
• Partners and collaborators could experience disruptions or terminations of agreements if the company's financial condition deteriorates or if product development timelines are significantly impacted.

Next Steps

• Receive FDA file acceptance for the INO-3107 BLA by the end of 2025.
• Await potential FDA priority review for INO-3107, expected to be completed within six months following the 60-day filing period if granted.
• Initiate a confirmatory clinical trial for INO-3107, a requirement for accelerated approval, prior to BLA submission.
• Conduct a planned Phase 3 clinical trial for INO-3112 for OPSCC in collaboration with Coherus BioSciences.
• Seek additional capital through strategic alliances, licensing arrangements, grant agreements, and/or future public or private debt or equity financings to meet capital needs beyond Q2 2026.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on financial condition and results of operations.

Key Dates

Recommendation

The company's financial position is highly precarious, marked by significant net losses, a substantial accumulated deficit, negative working capital, and an explicit 'going concern' warning from management. While there is some clinical progress with the INO-3107 BLA submission, the severe liquidity risk, ongoing cash burn, and the necessity for substantial additional capital in a challenging market environment make the stock a high-risk investment. The likelihood of further shareholder dilution and potential capital loss is significant, outweighing the speculative upside of pipeline developments for a seasoned investor.

Keywords

INOVIO, DNA medicines, CELLECTRA, RRP, INO-3107, Biotechnology, Clinical-stage, HPV, Cancer, Infectious Diseases, Recurrent Respiratory Papillomatosis, OPSCC, Glioblastoma Multiforme, FDA, BLA, Regulatory Approval, Going Concern, Financial Results, Q3 2025, 10-Q, Capital Raise